Fulcrum Therapeutics (NASDAQ:FULC) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Fulcrum Therapeutics (NASDAQ:FULC) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other equities analysts have also issued reports on the company. Royal Bank Of Canada boosted their price objective on Fulcrum Therapeutics from $5.00 to $7.00 and gave the company a “sector perform” rating in a research report on Thursday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Fulcrum Therapeutics in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up from $12.50) on shares of Fulcrum Therapeutics in a research report on Thursday. Finally, Leerink Partners set a $20.00 target price on Fulcrum Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Fulcrum Therapeutics Trading Up 3.1%

Fulcrum Therapeutics stock opened at $9.02 on Friday. The firm has a market capitalization of $488.16 million, a P/E ratio of -7.64 and a beta of 3.02. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $10.11. The business has a 50-day moving average of $8.25 and a 200-day moving average of $7.11.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FULC. Jump Financial LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $30,000. Brooklyn Investment Group raised its stake in shares of Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after purchasing an additional 8,254 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $39,000. Russell Investments Group Ltd. raised its stake in shares of Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.